Integra LifeSciences cuts 2026 guidance after Cincinnati flood

Flooding at Integra's Ohio manufacturing site will cost up to $27m in lost revenue across Q3 and Q4, prompting a downgrade to full-year

The Biotech Times Editorial Team By The Biotech Times Editorial Team AI level 2 of 5
AI level 2 of 5: drafted by our AI editorial assistant from the company's announcement; fact-checked, edited and signed off by Mark Walker, Editorial Director. What the levels mean
Rows of white industrial robotic arms with black bases line a brightly lit, sterile cleanroom leading to a double door in the background.

Integra LifeSciences has revised its full-year 2026 financial guidance downward after flood damage to its Cincinnati manufacturing facility in July disrupted production of several Specialty Surgical Technologies products. The Princeton, New Jersey-based medical device maker now expects reported revenue of $1.634 billion to $1.654 billion for the year, compared with a prior range of $1.654 billion to $1.695 billion.

The company estimates the flooding reduced third-quarter revenue by approximately $7 million and expects a further $15 million to $20 million hit in the fourth quarter, implying a combined supply disruption impact of up to $27 million. Third-quarter revenue is now expected to land at $410 million to $412 million, with adjusted earnings per diluted share of $0.55 to $0.59. The adjusted EPS guidance for the full year has been trimmed to $2.30 to $2.40, from a prior range of $2.40 to $2.50.

Recovery timeline and insurance

Integra said the Cincinnati site, which supports several products within its Specialty Surgical Technologies portfolio, is not expected to return to full manufacturing capacity until the second quarter of 2027. In the interim, the company has drawn on existing inventory buffers and activated pre-established alternate supply arrangements for certain product lines.

Chairman and chief executive Stuart Essig said the company had made "significant progress" executing its recovery plans and that insurance cover would mitigate a substantial portion of the earnings impact. Integra holds both property damage and business interruption insurance on the facility and is working with its carrier to document recoverable losses. Full-year operating cash flow guidance remains broadly intact at $190 million to $200 million, a figure Essig described as reflecting continued strong cash generation despite the operational setback.

Market context and competitive read-across

Manufacturing disruptions of this kind are a recurring operational risk across the medical device sector, where products with specialised production processes can be difficult to substitute at short notice. Integra's neurosurgery and tissue reconstruction portfolio includes a number of differentiated, lower-volume technologies where inventory buffers are typically thinner than in high-volume commodity device categories.

The company's ability to absorb the disruption without more severe guidance cuts reflects both the insurance backstop and what management describes as improving commercial execution across the broader business. Investors will note, however, that a return to full Cincinnati capacity in Q2 2027 leaves a further two quarters of constrained output, with the larger quarterly impact falling in Q4 2026.

Broader trends in the medical device sector suggest buyers remain cautious about single-site manufacturing concentration, a topic that regulators including the US Food and Drug Administration have raised in guidance on supply chain resilience. Integra did not indicate whether it intends to seek additional geographic diversification of the affected manufacturing lines once the recovery is complete.

The company will report full third-quarter results on a conference call in October 2026, at which point it expects to provide more detailed commentary on the financial impact and the forward outlook.

Sector

Topic

Geography